A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

Simon Plummer (Lead / Corresponding author), Stephanie Wallace, Graeme Ball, Roslyn Lloyd, Paula Schiapparelli, Alfredo Quiñones-Hinojosa, Thomas Hartung, David Pamies

Research output: Contribution to journalArticle

2 Citations (Scopus)
50 Downloads (Pure)

Abstract

A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

Original languageEnglish
Article number1407
Pages (from-to)1-11
Number of pages11
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 5 Feb 2019

Fingerprint

temozolomide
Precision Medicine
Glioblastoma
Brain Neoplasms
Doxorubicin
Pharmaceutical Preparations
Neoplasms
Brain
Therapeutics
Neuroglia
Astrocytes
Histology
Apoptosis
Neurons

Cite this

Plummer, S., Wallace, S., Ball, G., Lloyd, R., Schiapparelli, P., Quiñones-Hinojosa, A., ... Pamies, D. (2019). A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Scientific Reports, 9(1), 1-11. [1407]. https://doi.org/10.1038/s41598-018-38130-0
Plummer, Simon ; Wallace, Stephanie ; Ball, Graeme ; Lloyd, Roslyn ; Schiapparelli, Paula ; Quiñones-Hinojosa, Alfredo ; Hartung, Thomas ; Pamies, David. / A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. In: Scientific Reports. 2019 ; Vol. 9, No. 1. pp. 1-11.
@article{5cf8a9a30ed349099e76a90558e6529c,
title = "A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine",
abstract = "A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30{\%} (P~0.07) and ~80{\%} (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.",
author = "Simon Plummer and Stephanie Wallace and Graeme Ball and Roslyn Lloyd and Paula Schiapparelli and Alfredo Qui{\~n}ones-Hinojosa and Thomas Hartung and David Pamies",
note = "Supported by NIH grants CA183827 and CA195503.",
year = "2019",
month = "2",
day = "5",
doi = "10.1038/s41598-018-38130-0",
language = "English",
volume = "9",
pages = "1--11",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Plummer, S, Wallace, S, Ball, G, Lloyd, R, Schiapparelli, P, Quiñones-Hinojosa, A, Hartung, T & Pamies, D 2019, 'A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine', Scientific Reports, vol. 9, no. 1, 1407, pp. 1-11. https://doi.org/10.1038/s41598-018-38130-0

A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. / Plummer, Simon (Lead / Corresponding author); Wallace, Stephanie; Ball, Graeme; Lloyd, Roslyn; Schiapparelli, Paula; Quiñones-Hinojosa, Alfredo; Hartung, Thomas; Pamies, David.

In: Scientific Reports, Vol. 9, No. 1, 1407, 05.02.2019, p. 1-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

AU - Plummer, Simon

AU - Wallace, Stephanie

AU - Ball, Graeme

AU - Lloyd, Roslyn

AU - Schiapparelli, Paula

AU - Quiñones-Hinojosa, Alfredo

AU - Hartung, Thomas

AU - Pamies, David

N1 - Supported by NIH grants CA183827 and CA195503.

PY - 2019/2/5

Y1 - 2019/2/5

N2 - A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

AB - A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

UR - http://www.scopus.com/inward/record.url?scp=85061124735&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-38130-0

DO - 10.1038/s41598-018-38130-0

M3 - Article

VL - 9

SP - 1

EP - 11

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1407

ER -